The Economics of Vaccines | Big Think

TL;DR

Vaccines' market dynamics shift, requiring global public-private partnerships to foster innovation amid scientific, political, and financial challenges.

Transcript

it's interesting because vaccines used to be thought as not very profitable you know the pharmaceutical industry much much larger people when they're sick of course will have a perception that you know they'll pay more because you know they they're worried about uh about being sick and wanting to get better there's nothing that's more driving than ... Read More

Key Insights

• 💄 Vaccine market dynamics have shifted, making once non-profitable vaccines profitable for pharmaceutical companies.
• ❓ Challenges in vaccine development include scientific complexity, political controversies, and financial viability, hindering progress.
• 🌐 Global public-private partnerships are essential to incentivize innovation in vaccine development for global health benefits.
• 👨‍🔬 Advanced market commitments, tax credits, and research funding are crucial incentives to engage scientists and companies in vaccine development.
• 🧑‍⚕️ Product development partnerships in the health sector drive innovation, with examples like Airbus consortia's success in combining public and private sectors.
• 🥺 The shift towards public-private partnerships in vaccine development has led to a renaissance of new products for diseases of poverty.
• 🪛 Academic and industry partnerships, like those in the semiconductor industry, showcase the success of collaboration in driving innovation.

Questions & Answers

Q: Why have vaccines transitioned from being non-profitable to profitable in the pharmaceutical industry?

Vaccines have become profitable due to the creation of high-priced products targeting large markets, emphasizing the pharmaceutical industry's pursuit of blockbusters for financial success.

Q: What challenges hinder vaccine development?

Vaccine development faces obstacles like scientific complexity, political controversies related to disease topics like sex, and financial viability concerns with markets in the developing world.

Q: How can global public-private partnerships address these challenges?

By creating incentives like advanced market commitments, tax credits, and research funding, partnerships can engage top scientists and companies to drive vaccine innovation for diseases of poverty.

Q: What role do public-private partnerships play in vaccine development?

Public-private partnerships bring together the expertise of government and private sectors to overcome obstacles and facilitate the development of vaccines for global health challenges.

Summary & Key Takeaways

• Vaccines, once seen as non-profitable public health necessities, are now pursued as lucrative markets.

• Developing vaccines faces challenges due to scientific complexity, political controversies, and financial viability.

• Global public-private partnerships are crucial to incentivize scientists and companies to invest in vaccine development for global benefit.